SMALL CELL LUNG CARCINOMA

This early-stage study tests a new drug combination (BMS-986489) in 10 Chinese adults with small cell lung cancer that has returned or stopped responding to treatment. The main goals are to check safety and how the drug moves through the body, while also looking for signs that it…

This early-stage study tests a drug called tarlatamab in about 269 people with small cell lung cancer that has come back or not responded to standard treatment. The main goal is to check the drug's safety and how the body processes it. Researchers will monitor side effects and me…

This study tests a new three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with small cell or non-small cell lung cancer whose disease has worsened after initial treatment. The first part of the study finds the safest dose, and the second part checks how wel…

This study tests whether adding tiragolumab to standard atezolizumab and chemotherapy helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 participants in China will receive either the triple combination or a place…

This study follows 254 adults with extensive-stage small cell lung cancer, a fast-growing cancer, to see how well durvalumab (an immunotherapy) works with standard chemotherapy in everyday medical practice. The main goal is to measure how long patients stay on treatment, and rese…

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This study tests whether a drug called durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from getting worse after standard chemotherapy and radiation. About 100 participants who are older, have a weaker health status, or couldn't get …